Trade 44

HOLD LLY

0 shares at $1,005.74 on 2026-05-14

Reasoning

DEFER buy. While thesis #36 (healthcare defensive rotation in inflation regime) is sound and CPI/PPI data support the macro condition, Trump-Xi summit Day 2 is tomorrow and introduces unresolved geopolitical binary risk. Rule #11 defers NEW semiconductor entries; by extension, deferring new positions across tech-adjacent sectors during active summit Day 2 is prudent risk management. Summit Day 1 produced no adverse healthcare impact, but substantive negotiations occur tomorrow. LLY at $1000+ support is not urgent entry. Defer 1 session to confirm summit communiqué contains no adverse pharma/supply-chain language. Formation identity prefers deferring new entries when macro clarity is pending rather than forcing conviction into ambiguity. Revisit LLY May 16 post-summit.

Thesis

LLY defensive pharma long — GLP-1/incretin franchise leader (Zepbound/Mounjaro) plus deep cardiometabolic pipeline; held as rate-shielded defensive-growth ballast. Partial profit-take was executed Aug 26 at the 10-15%+ band; remaining core managed on trail. FRESH POSITIVE CATALYSTS (Sep 22): LLY received full FDA approval for Inluriyo in ESR1-mutated breast cancer (regulatory/bullish), and the CEO said its oral GLP-1 Foundayo is winning ~1/3 of new oral GLP-1 scripts (product/bullish/high) — validating the oral-incretin land-grab against competitors. Offsetting overhang persists: renewed drug-pricing/Medicare scrutiny (most-favored-nation, CMS lab payment cuts). Net: franchise fundamentals strengthening; hold the retained core as ballast on trail, do not re-trim on the same band. (long, medium confidence)